|
|
|
|
Based on available evidence, Andexanet represents low value for reversal of factor Xa-associated ICrH; however, there is substantial uncertainty reflecting the currently available data. Further comparative evidence and costing data will become available in the future with randomized trial of Andexanet versus PCC. |
|